| Literature DB >> 23876131 |
Yuta Aoki1, Osamu Abe, Yasumasa Nippashi, Hidenori Yamasue.
Abstract
BACKGROUND: Aberrant brain connectivity, especially with long-distance underconnectivity, has been recognized as a candidate pathophysiology of autism spectrum disorders. However, a number of diffusion tensor imaging studies investigating people with autism spectrum disorders have yielded inconsistent results.Entities:
Year: 2013 PMID: 23876131 PMCID: PMC3726469 DOI: 10.1186/2040-2392-4-25
Source DB: PubMed Journal: Mol Autism Impact factor: 7.509
Summary of studies included in the whole brain analysis diffusion tensor imaging group
| | | | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | | |||||||||||||||||||||
| Ameis and colleagues [ | 19 | 16 | 12.4 | 99 | 16 | 8 | 12.3 | 101 | DSM-IV/ADI-R/ADOs | No/No | 3 | 1,250 | 12 | 5 | 80/4,100 | TBSS | FSL4.1 | ○ | ○ | ○ | ○ | ○ | ○ | ○ | MD↓ in UF, IFOF, CC, SLF, in ASD children | |||
| Barnea-Goraly and colleagues [ | 7 | 7 | 14.6 | 101 | 9 | 9 | 13.4 | 107 | ADI-R/ADOS | NA/Na | 3 | 900 | 6 | 4 | 106/6,000 | Voxel Based Whole Brain | SPM99 | ○ | FA↓ in Cg, UF, in ASD | |||||||||
| Barnea-Goraly and colleagues [ | 13 | 11 | 10.5 | 86 | 11 | 9 | 9.6 | 120 | ADI-R/ADOS | NA/No | 1.5 | 900 | 6 | 4 | 106/6,000 | TBSS | FSL4.1 | ○ | ○ | ○ | ○ | ○ | ○ | FA↓ in CC, SLF, in ASD | ||||
| Bloemen and colleagues [ | 13 | 113 | 39 | 110 | 13 | 13 | 37 | 115 | ICD-10/ADI-R/ADOS | NA/No | NA | 1,300 | 4 | NA | 107/15,000 | Voxel Based Whole Brain | SPM2 | ○ | ○ | ○ | NA | NA | ○ | FA↓ in IFOF, ILF, CC, SLF, Cg, in ASD | ||||
| Bode and colleagues [ | 27 | 20 | 14.7 | NA | 26 | 17 | 14.5 | NA | ADI-R/ADOS | NA/No | NA | 100 | NA | 1 | 90/8,000 | TBSS | FSL | ○ | ○ | NA | NA | FA↓ in IFOF | ||||||
| Cheung and colleagues [ | 13 | 12 | 9.3 | 100 | 14 | 13 | 9.9 | 112 | ICD-10/ADI-R | No/No | 1.5 | 1,200 | 25 | NA | 100/10,000 | Voxel Based Whole Brain | SPM2 | ○ | FA↓ in SLF, FA, in ASD | |||||||||
| Groen and colleagues [ | 17 | 14 | 14.4 | 98 | 25 | 22 | 15.5 | 105 | ADI-R | No/No | 1.5 | 900 | 30 | 4 | 93/10,100 | Voxel Based Whole Brain | SPM5 | ○ | ○ | ○ | FA↓ in SLF, ILF, in ASD | |||||||
| Jeong and colleagues [ | 32 | 29 | 439 | NA | 14 | 11 | 5.61 | NA | DSM-IV | NA/No | 3 | 1,000 | 6 | 6 | NA/1,250 | Whole Brain Tractography | FSL | ○ | ○ | Various | ○ | FA↓ in, AF <UF, CC in ASD | ||||||
| Jou and colleagues [ | 15 | 15 | 10.9 | NA | 8 | 8 | 11.5 | NA | DSM-IV/ADI-ADOS | NA/NA | 3 | NA | 30 | 3 | 85/6,200 | TBSS | FSL | ○ | ○ | ○ | NA | NA | ○ | FA↓ in IFOF, SLF, UF, Cg, in ASD | ||||
| Jou and colleagues [ | 10 | 10 | 13.5 | 91 | 10 | 10 | 13.5 | 105 | DSM-IV/ADI-R/ADOS | NA/NA | 1.5 | 1,000 | 6 | 6 | 92/1,1200 | Voxel Based Whole Brain | Biolmage Suite | ○ | p<0.05 | FA↓ in CC, CG, SLF, IFOF, ILF, in ASD | ||||||||
| Ke and colleagues [ | 12 | 12 | 8375 | 101 | 12 | 12 | 9.4 | 100 | DSM-IV/ADI-R | NA/No | 1.5 | 1,000 | 15 | 2 | 104.4/8,000 | Voxel Based Whole Brain | SPMS | ○ | p<0.05 | No peak coordinates reported in cortical fibers | ||||||||
| Kumar and colleagues [ | 32 | 29 | 5 | NA | 16 | 12 | 5.5 | NA | DSM-IV | NA/No | 3 | 1,000 | 6 | 6 | 79/1,0000 | TBSS | FSL | ○ | ○ | p<0.05 | FA↓ in rt UF, IFO, AF, rt Cg, CC in ASD | |||||||
| Noriuchi and colleagues [ | 7 | 6 | 14 | 93 | 7 | 6 | 13.4 | 116 | DSM-IV | NA/NA | 3 | 800 | 32 | NA | 88/7,420 | Voxel Based Whole Brain | SPM2 | ○ | p<0.05 | ○ | FA↓ in SLF, CC, Cg, in ASD | |||||||
| Sahyoun and colleagues [ | 12 | 9 | 12.8 | 101 | 12 | 9 | 13.3 | 106 | DSM-IV/ADI-R | No/NA | 3 | 700 | 60 | NA | 84/7,980 | TBSS | FSL | ○ | ○ | p<0.05 | NA | NA | ○ | FA↑ in bl UF, rt SLF, FA↓ in bl, SLF, bl FOF in ASD | ||||
| Thakkar and colleagues [ | 12 | 10 | 30 | 116 | 14 | 8 | 27 | 114 | DSM-IV/ADI-R/ADOS | Yes/No | 3 | 700 | 60 | NA | 82/8,400 | Voxel Based Whole Brain | FSL | ○ | p<0.05 | NA | NA | FA↓ in Cg in ASO | ||||||
| Weinstein and colleagues [ | 21 | NA | 3.3 | NA | 26 | NA | 3.3 | NA | DSM-IV/ADI-R/ADOS | NA/No | 1.5 | 1,000 | 15 | 2 | 94/1,1000 | TBSS | FSL 0 | ○ | ○ | ○ | ○ | p<0.05 | NA | NA | ○ | FA↑ in lt SLF, bl Cg, CC in ASD | ||
aNumber of ASD participants. bMean IQ of participants. cNumber of controls. AD axial diffusivity, ADC apparent diffusion coefficient, ADIR Autism Diagnostic Interview-Revised, ADOS Autism Diagnostic Observation Schedule, ASD autism spectrum, AF arcuate fasciculus, bl bilateral, CC corpus callosum, Cg cingulum, DSM-IV Diagnostic and Statistical Manual of Mental Disorders-IV, FA fractional anisotropy, FDR false discovery rate, FSL FMRIB Software Library, FWE family wise error, ICD-10 International Statistical Classification of Diseases and Related Health Problems-10, IFOF inferior frontal occipital fasciculus, ILF inferior frontal occipital fasciculus, lt left, MD mean diffusivity, NA not available, NEX number of excitation, RD radial diffusivity, rt right, SLF superior longitudinal fasciculus, SPM statistical parametric mapping, TBSS tract-based spatial statistics, TD typically developing, TE echo time, TFCE threshold, free cluster enhancement, TR repetition time, UF uncinate fasciculus, WBA whole brain analysis.
Figure 1The process used for the study selection. ASD, autism spectrum disorder; ROI, region of interest; TD, typical development; WBA, whole brain analysis.
Summary of studies included in the regions-of-interest group
| | | | | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | ||||||||||||||||||||||||||||
| Alexander and colleagues [ | 43 | 43 | 16.2 | 107 | 34 | 34 | 16.4 | 113 | DSM-IV/ICD-10/ADI-R/ADOS-G | Yes/Yes | 3 | 1,000 | 12 | 4 | 84/7,000 | ROI | ○ | ○ | ○ | ○ | ○ | ||||||||
| Ameis and colleagues [ | 19 | 16 | 12.4 | 98.5 | 16 | 8 | 12.3 | 101 | DSM-IV/ADI-R/ADOS | No/No | 3 | 1,250 | 12 | 5 | 80/4,100 | ROI | ○ | ○ | ○ | ○ | ○ | ||||||||
| Beacher and colleagues [ | 28 | 15 | 32 | NA | 30 | 15 | 30 | NA | DSM-IV | Yes/No | 1.5 | 1,000 | 64 | NA | 95/8,000 | ROI | ○ | ○ | |||||||||||
| Ben Bashat and colleagues [ | 17 | NA | NA | NA | NA | NA | 9.6 | NA | DSM-IV/ADI-R/ADOS | NA/NA | 1.5 | 6,000 | 6 | 4 | 128/1,800 | ROI | ○ | ○ | ○ | ○ | ○ | ||||||||
| Brito and colleagues [ | 8 | 8 | 9.53 | NA | 8 | 8 | 9.57 | NA | DSM-IV | Yes/No | 1.5 | 100 | 12 | 3 | 90/3,100 | | ○ | ○ | |||||||||||
| Catani and colleagues [ | 15 | 15 | 31 | 109 | 16 | 16 | 35 | 120 | ICD-10/ADI/ADOS | NA/No | 1.5 | 1,300 | 64 | NA | 107/1,500 | Tractography | ○ | ○ | ○ | ○ | ○ | ||||||||
| Cheon and colleagues [ | 17 | 17 | 11 | 112 | 17 | 17 | 10.2 | 114 | DSM-IV/ ADI-R/ADOS | Yes/No | 1.5 | 900 | 30 | 2 | 86/6500 | ROI | ○ | ○ | |||||||||||
| Conturo and colleagues [ | 17 | 14 | 26.5 | 104 | 17 | 14 | 26.1 | 105 | ADI-R/ADOS | Yes/No | 1.5 | NA | 7 | 10 | 94/1,51750 | Tractography | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ||||||
| Fletcher and colleagues [ | 10 | 10 | 14.3 | 106 | 10 | 10 | 13.4 | 108 | DSM-IV/ICD-10/ADI-R/ADOS | NA/NA | 3 | 1,000 | 12 | 4 | 84/700 | ROI | |||||||||||||
| Hong and colleagues [ | 18 | 18 | 8.69 | 105 | 16 | 16 | 9.81 | 106 | DSM-IV/ADI-R | No/No | 1.5 | 1,000 | 15 | 2 | 104.4/8,000 | ROI | ○ | ○ | ○ | ||||||||||
| Ingalhalikar and colleagues [ | 45 | 42 | 10.5 | NA | 30 | 14 | 10.3 | NA | NA | NA/NA | 3 | 1,000 | 15 | NA | 70/16,900 | ROI | ○ | ○ | |||||||||||
| Knaus and colleagues [ | 14 | 14 | 16.1 | 103 | 20 | 20 | 14.1 | 116 | DSM-IV/ADI-ADOS | NA/No | 3 | 1,000 | 15 | NA | N/A | Tractography | ○ | ○ | |||||||||||
| Kumar and colleagues [ | 32 | 29 | 5 | NA | 16 | 12 | 5.5 | Na | DSM-IV | NA/No | 3 | 1,000 | 6 | 6 | 79/10,000 | Tractography | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ||||||
| Langen and colleagues [ | 21 | 21 | 25.6 | 107 | 22 | 22 | 28.5 | 110 | ICD-10/ADI-R/ADOS | No/No | 3 | 1,300 | 32 | NA | 107/10,000 | Tractography | ○ | ○ | ○ | ○ | |||||||||
| Leemans and Jones [ | 43 | 43 | 16.2 | 108 | 34 | 34 | 16.4 | 113 | DSM-IV/ICD-10/ADI-R/ADOS-G | NA/No | 3 | 1,000 | 12 | 3 | 84/7,000 | ROI | ○ | ○ | ○ | ○ | |||||||||
| Lo and colleagues [ | 15 | 15 | 15.2 | 108 | 15 | NA | 15 | 111 | DSM-IV/ICD-10/ADI-R | NA/No | 3 | 6,000/4,000 | 102 | NA | 142/9,100, 130/9,600 | ROI | ○ | ○ | ○ | ○ | ○ | ||||||||
| Poustka and colleagues [ | 18 | 16 | 19.7 | 111 | 18 | 16 | 9.7 | 113 | ICD-10/ADI/ADOS | NA/No | 1.5 | 1,000 | 6 | 15 | 78/4,700 | ROI | ○ | ○ | ○ | ○ | ○ | ||||||||
| Pugliese and colleagues [ | 24 | 24 | 23.3 | 105 | 24 | 24 | 25.3 | 121 | ICD-10/ADI-R | No/No | NA | 1,300 | 32 | NA | 107/15,000 | Tractography | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ||||||
| Sahyoun and colleagues [ | 9 | 7 | 12.8 | 101 | 12 | 9 | 13.3 | 106 | ADIM-IV/ADI-R | No/No | 3 | 700 | 60 | Na | 84/7,980 | ROI | ○ | ||||||||||||
| Shukla and colleagues [ | 24 | 24 | 5 | NA | 16 | 12 | 5.9 | NA | ADI-R/ADOS | Yes/No | 3 | 200 | 15 | 4 | 99.4/1,0000 | ROI | | ○ | ○ | ○ | ○ | ||||||||
| Sivaswamy and colleagues [ | 27 | 24 | 5 | NA | 16 | 12 | 5.9 | NA | DSM-IV | Yes/No | 3 | 1,000 | 6 | 6 | 160/11000 | ROI | ○ | ||||||||||||
| Sundaram and colleagues [ | 50 | 43 | 4.79 | NA | 16 | 11 | 6.84 | NA | DSM-IV0 | Yes/No | 3 | 1,000 | 6 | 6 | 79/10,000 | Tractography | ○ | ○ | |||||||||||
| Thomas and colleagues [ | 12 | 12 | 28.5 | 107 | 18 | 18 | 22.4 | 112 | DSM-IV/ ADI-R/ADOS | NA/No | 3 | 850 | 6 | 12 | 82/4,900 | ROI | ○ | ○ | ○ | ○ | |||||||||
| Verhoeven and colleagues [ | 19 | 16 | 13.8 | NA | 33 | 24 | 12.9 | NA | DSM-IV | Yes/No | 3 | 800 | 45 | 2 | 55/11,043 | Tractography | ○ | ○ | ○ | ||||||||||
| Weinstein and colleagues [ | 22 | NA | 3.2 | NA | 28 | NA | 3.6 | NA | DSM-IV ADI-R/ADOS | NA/Yes | 1.5 | 1,000 | 15 | 2 | 94/11,043 | Tractography | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ||||||
aNumber of ASD participants. bMean IQ of participants. cNumber of controls. AD axial diffusivity, ADC apparent diffusion coefficient, ADIR Autism Diagnostic Interview-Revised, ADOS Autism Diagnostic Observation Schedule, AF arcuate fasciculus, ASD autism spectrum disorder, CC corpus callosum, Cg cingulum, DSM-IV Diagnostic and Statistical Manual of Mental Disorders-IV, FA fractional anisotropy, Fo fornix, ICD-10 International Statistical Classification of Diseases and Related Health Problems-10, IFOF inferior frontal occipital fasciculus, ILF inferior longitudinal fasciculus, MD mean diffusivity, NA not available, NEX number of excitation, RD radial diffusivity, ROI region of interest, SLF superior longitudinal fasciculus, TD typically developing, TE echo time, TR repetition time, UF uncinate fasculus.
Figure 2Significant findings from the meta-analyses in the corpus callosum and left uncinate fasciculus. Forest plots of the meta-analyses of fractional anisotropy (FA) (upper), mean diffusivity (MD) in the corpus callosum (CC) (middle) and MD in the left uncinate fasciculus (UF) (lower). Mean and standard deviation (SD) of age of individuals with autism spectrum disorders (ASDs) are demonstrated at the end of each study name. Studies are lined in the order of mean age from the youngest (top) to the oldest (bottom).
Meta-analysis by tract and value
| Corpus callosum | NA | FA | 9 | 208 | 179 | −1.087 | −0.081 | −2.275 | 0.023 | 81.91 | 0.541 |
| MD | 6 | 129 | 125 | 0.163 | 0.950 | 2.770 | 0.006 | 53.81 | 0.650 | ||
| Urinate fasciculus | Left | FA | 6 | 117 | 125 | −0.872 | −0.115 | −2.553 | 0.011 | 49.76 | 0.279 |
| MD | 4 | 60 | 75 | −0.148 | 1.300 | 1.584 | 0.113 | 73.96 | 0.682 | ||
| Right | FA | 6 | 116 | 124 | −0.998 | 0.203 | −1.237 | 0.216 | 75.81 | 0.027 | |
| MD | 4 | 60 | 75 | 0.123 | −0.410 | 0.963 | 0.790 | 69.11 | 0.636 | ||
| Cingulum | Left | FA | 5 | 101 | 109 | −0.846 | 0.224 | −1.139 | 0.255 | 69.80 | 0.633 |
| Right | FA | 5 | 101 | 109 | −00.475 | 0.525 | 0.099 | 0.921 | 65.94 | 0.857 | |
| Superior longitudinal fasciculus | Left | FA | 5 | 96 | 86 | −0.954 | −0.097 | −2.404 | 0.016 | 48.34 | 0.707 |
| MD | 4 | 51 | 58 | 0.062 | 1.256 | 2.163 | 0.031 | 49.66 | 0.950 | ||
| Right | FA | 5 | 92 | 82 | −0.682 | 0.158 | −1.229 | 0.219 | 43.99 | 0.462 | |
| MD | 4 | 51 | 58 | 0.140 | 1.100 | 2.534 | 0.011 | 26.11 | 0.499 | ||
| Inferior longitudinal fasciculus | Left | FA | 4 | 61 | 85 | −1.491 | 0.313 | −1.279 | 0.201 | 83.19 | 0.907 |
| Right | FA | 4 | 61 | 85 | −0.775 | 0.000 | −1.959 | 0.050 | 20.15 | 0.207 | |
| Inferior frontal occipital fasciculus | Left | FA | 3 | 68 | 76 | −0.979 | 0.195 | −1.309 | 0.191 | 63.22 | 0.690 |
| Right | FA | 3 | 68 | 76 | −0.735 | 0.152 | −1.287 | 0.198 | 37.41 | 0.528 |
aNumber of ASD participants. bNumber of controls. ASD autism spectrum disorder, CI confidence interval, FA fractional anisotropy, MD mean diffusivity.
Figure 3Significant findings from the meta-analyses in the superior longitudinal fasciculus. Forest plots of the meta-analyses of fractional anisotropy (FA) (upper) and mean diffusivity (MD) (middle) in the left superior longitudinal fasciculus (SLF) and MD in the right SLF (lower). Mean and standard deviation (SD) of age of individuals with autism spectrum disorders (ASDs) are demonstrated at the end of each study name. Studies are lined in the order of mean age from the youngest (top) to the oldest (bottom).
Figure 4Summary of the main findings. The fractional anisotropy (FA) was significantly decreased, whereas the mean diffusivity (MD) was significantly increased in the corpus callosum (CC) in subjects with autism spectrum disorders (ASDs) compared with TD individuals. The FA was significantly decreased in individuals with ASDs in the left (lt) but not in the right (rt) uncinate fasciculus (UF). There was no significant difference in MD values in the UF between subjects with ASDs and TD individuals. The FA was significantly decreased in the left superior longitudinal fasciculus (SLF) but not in the right SLF. The MD was significantly increased in the SLF bilaterally.